Application of ginsenoside GRh2 in preparing toxoplasma gondii resisting compound preparation and medicine thereof

A technology of ginsenosides and compound preparations, applied in the directions of anti-infectives, drug combinations, pharmaceutical formulations, etc., can solve the problems of high toxicity and low efficiency of toxoplasmosis prevention and control drugs, and achieve the effects of prolonging survival time and inhibiting the proliferation of Toxoplasma gondii

Active Publication Date: 2018-11-27
YANBIAN UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In order to solve the problems of low efficiency and high toxicity of drugs for preventing and treating toxoplasmosis in the prior art, the present invention provides an application of ginsenoside GRh2 in the preparation of drugs for preventing and treating toxoplasmosis, especially anti-toxoplasmic encephalitis. Ginsenoside GRh2 It has a good inhibitory effect on Toxoplasma gondii, has a protective effect on the host infected by Toxoplasma gondii, and basically has no toxic side effects at an effective dose

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginsenoside GRh2 in preparing toxoplasma gondii resisting compound preparation and medicine thereof
  • Application of ginsenoside GRh2 in preparing toxoplasma gondii resisting compound preparation and medicine thereof
  • Application of ginsenoside GRh2 in preparing toxoplasma gondii resisting compound preparation and medicine thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Embodiment 1 GRh2 resists Toxoplasma gondii infection and protects the host

[0058] 1 Experimental materials

[0059] 1.1 Experimental drugs

[0060] (S type) ginsenoside GRh2 (Shanghai Yuanye Biotechnology Co., Ltd., batch number: HA0408XB14, HPLC≥98%); (R type) ginsenoside GRh2 (Shanghai Yuanye Biotechnology Co., Ltd., batch number: Z14S63238, HPLC≥98%) ); positive control drugs: sulfadiazine (SD) (SIGMA-ALORICH, CAS: 68-35-9, 35033-100mg), sulfadiazine sodium (SD-Na) (Aladdin Industrial Corporation, CAS: 68-35-9, 35033-100mg).

[0061] 1.2 Experimental materials

[0062] Toxoplasma gondii: international standard virulent strain Toxoplasma gondii RH strain (ATCC); 50 SPF Balb / c female mice, weighing (20±2) g (Liaoning Changsheng Biotechnology Co., Ltd.); BV2 cells (ATCC) ;

[0063] DMEM medium (Gibco), fetal bovine serum FBS (Gibco); dimethyl sulfoxide DMSO (Sigma); MTT (Sigma); RIPA high-efficiency lysate (Solarbio); PMSF (Beiyuntian), BCA protein quantificatio...

Embodiment 2

[0149] The preparation of embodiment 2 GRh2 tablet

[0150] Raw materials and their dosage: 25g of GRh, 30g of mannitol, 2g of sodium carboxymethylcellulose and 1g of magnesium stearate.

[0151] Preparation process: drying each raw material, crushing and sieving through a 100-mesh sieve for pretreatment, mixing the main drug GRh2 with mannitol and sodium carboxymethylcellulose as auxiliary materials, adding an appropriate amount of 70% ethanol to make a soft material, passing through 14 mesh Sieve to form granules, blow dry at 55°C for 2 hours, sieve with 16 mesh and 100 mesh, add magnesium stearate and mix well, and press the mixture into tablets of appropriate size and weight to obtain GRh2 oral tablets.

Embodiment 3

[0152] Example 3 Preparation of GRh2 Injection

[0153] Raw material and dosage: GRh210g, PEG-4002.5L and normal saline for injection are added to 10L.

[0154] Preparation process: add GRh2 to the prescribed amount of PEG-400, stir to dissolve, add physiological saline for injection to make the final volume 10L and stir evenly. Sampling was taken to determine the pH value and content, and filtered through a 0.22 μm microporous membrane after passing the test. The GRh2 injection is obtained by aseptic potting.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicines, and provides the application of ginsenoside GRh2 in preparing a toxoplasma gondii resisting compound preparation. GRh2 can effectively inhibit the proliferation of toxoplasma gondii when the GRh2 is separately taken as the effective ingredient to improve clinical performance of an infected mouse. The activation of microglia is inhibited by the GRh2through a TLR4 signal pathway to inhibit the overexpression of inflammatory factors, and the GRh2 has a certain protection effect on a host. In vitro pharmacodynamic tests show that the cytotoxicity of the GRh2 is small, the GRh2 has no significant difference with sulfadiazine in the proliferation inhibiting effect on the toxoplasma gondii under safety dosage and can significantly prolong the survival rate of a toxoplasma gondii infected host, the protecting effect of the GRh2 is significantly improved compared with the sulfadiazine, the GRh2 can reduce the amount of the toxoplasma gondii, thegrowth status of infected cells is almost close to that of normal cells, and the completeness of the morphology of toxoplasma gondii host cells can be effectively protected. The invention further provides the application of the ginsenoside GRh2 in preparing toxoplasma gondii vaccines.

Description

technical field [0001] The invention relates to the field of medicines, in particular to the application of ginsenoside GRh2 in the preparation of anti-toxoplasma compound preparations and the anti-toxoplasma gondii compound preparation containing ginsenoside GRh2. Background technique [0002] Toxoplasma gondii (Toxoplasma gondii) is an obligate intracellular parasitic protozoan that can infect almost all warm-blooded animals including humans, causing the zoonotic toxoplasmosis. Toxoplasmosis is distributed worldwide and the infection is relatively serious. According to survey statistics, the number of people infected with toxoplasmosis in the world is as high as 1 / 3 (Louis MW, Jitender PD. Toxoplasmosis: ahistory of clinical observations[J].Int JParasitol.2009,39(8 ): 895-901.; Sandra KH, Louis MW. TOXOPLASMOSIS [J]. Handb Clin Neurol. 2013, 114: 125-145.). [0003] According to the analysis of the second national survey on important human parasitic diseases, the seroposi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P33/02A61K39/39
CPCA61K31/704A61K39/39A61P33/02
Inventor 朴莲荀金澜姜彤徐翔金学军
Owner YANBIAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap